Kavar Capital Partners Group LLC Sells 410 Shares of Becton, Dickinson and Company (NYSE:BDX)

Kavar Capital Partners Group LLC cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,628 shares of the medical instruments supplier’s stock after selling 410 shares during the period. Becton, Dickinson and Company comprises 1.2% of Kavar Capital Partners Group LLC’s portfolio, making the stock its 23rd biggest position. Kavar Capital Partners Group LLC’s holdings in Becton, Dickinson and Company were worth $7,626,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Kingswood Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $229,000. Vicus Capital purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $601,000. Red Door Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. Red Door Wealth Management LLC now owns 1,437 shares of the medical instruments supplier’s stock valued at $356,000 after acquiring an additional 51 shares during the period. BKM Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 17.1% in the 1st quarter. BKM Wealth Management LLC now owns 4,891 shares of the medical instruments supplier’s stock valued at $1,210,000 after acquiring an additional 715 shares during the period. Finally, Claro Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 26.5% in the 1st quarter. Claro Advisors LLC now owns 2,852 shares of the medical instruments supplier’s stock valued at $706,000 after acquiring an additional 597 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $238.13 on Friday. The stock has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average of $237.46 and a 200 day moving average of $235.08.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.96 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analysts Set New Price Targets

BDX has been the topic of a number of analyst reports. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.